<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893019</url>
  </required_header>
  <id_info>
    <org_study_id>M-2015-307</org_study_id>
    <nct_id>NCT03893019</nct_id>
  </id_info>
  <brief_title>MB-CART20.1 Melanoma</brief_title>
  <official_title>Multicenter Phase I Trial of MB-CART20.1 for the Treatment of Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miltenyi Biomedicine GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DLR German Aerospace Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Miltenyi Biomedicine GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase l multi-centric, single arm, prospective, open, dose-escalation study in&#xD;
      patients with unresectable stage III oder IV melanoma. The trial will include 15 adult&#xD;
      patients. The trial is a classic 3+3 design with 1 Log dose increments and maximum 3 dose&#xD;
      levels of the intravenously administered MB-CART20.1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase I trial will be the first trial with CD20 CAR transduced T cells in Europe&#xD;
      targeting melanoma. The rationale for the trial is based on the finding that melanoma cancer&#xD;
      sustaining cells express CD20 and that targeting CD20+ cells in preclinical model has a&#xD;
      strong antitumor effect.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of MTD</measure>
    <time_frame>Week 4 after infusion of MB-CART20.1</time_frame>
    <description>MTD is defined as the highest dose level at which &lt; 33% of patients experience dose limiting toxicity (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Toxicity Assessment per Adverse Event reporting classified according to CTCAE V5.0</measure>
    <time_frame>until day 28 after infusion of MB-CART20.1</time_frame>
    <description>per Adverse Event reporting classified according to CTCAE V5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>1 year after infusion of MB-CART20.1</time_frame>
    <description>Number of patients with either Complete Response, Partial Response, Stable Disease or Progressive Disease using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of B-cell aplasia</measure>
    <time_frame>1 year after infusion of MB-CART20.1</time_frame>
    <description>Circulating B cell numbers in the peripheral blood will be assessed by Flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotype and Persistence of infused MB-CART20.1</measure>
    <time_frame>1 year after infusion of MB-CART20.1</time_frame>
    <description>Blood samples for determination of persistence/phenotyping of infused MB-CART20.1 will be analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and phenotype of MB-CART20.1 and B cells in biopsies</measure>
    <time_frame>Screening, 8 weeks after infusion of MB-CART20.1</time_frame>
    <description>Tumor biopsies for determination of persistence/phenotyping of infused MB-CART20.1 will be analysed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CD20+ tumor cells</measure>
    <time_frame>Screening, 8 weeks after infusion of MB-CART20.1</time_frame>
    <description>Tumor biopsies for determination of number of CD20+ tumor cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of T-cell expansion for each dose group</measure>
    <time_frame>Day 0 and week 12</time_frame>
    <description>Blood samples for determination MB-CART20.1 levels (transgene copies / genomic DNA)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Dose Level 1: 1x10e5 MB-CART20.1 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3+3 patients will be treated with 1x10e5 MB-CART20.1 cells per kg body weight administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2: 1x10e6 MB-CART20.1 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3+3 patients will be treated with 1x10e6 MB-CART20.1 cells per kg body weight administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3: 1x10e7 MB-CART20.1 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3+3 patients will be treated with 1x10e7 MB-CART20.1 cells per kg body weight administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MB-CART20.1</intervention_name>
    <description>MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells</description>
    <arm_group_label>Dose Level 1: 1x10e5 MB-CART20.1 cells</arm_group_label>
    <arm_group_label>Dose Level 2: 1x10e6 MB-CART20.1 cells</arm_group_label>
    <arm_group_label>Dose Level 3: 1x10e7 MB-CART20.1 cells</arm_group_label>
    <other_name>CD20-targeting CAR T cells</other_name>
    <other_name>anti-CD20 CAR T cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male or female patients with&#xD;
&#xD;
          -  Histologically confirmed unresectable stage III or stage IV melanoma&#xD;
&#xD;
          -  Willingness to provide a tumor biopsy between the screening visit and prior to&#xD;
             administration of the IMP and eight weeks after treatment&#xD;
&#xD;
          -  Progressive disease despite treatment with indicated standard therapies. Time window&#xD;
             for decision about progressive disease is to be made depending on the treatment&#xD;
             regimen chosen.&#xD;
&#xD;
          -  Measurable lesions according to RECIST1.1&#xD;
&#xD;
          -  ECOG (Eastern cooperative oncology group) performance status of 0-2&#xD;
&#xD;
          -  Negative serological hepatitis B (HBV) test defined as negative tests for HBsAg and&#xD;
             HBcAb, unless serology is positive due to recent IVIG therapy, HBcAb positivity will&#xD;
             be allowed if HbsAb is present, negative testing of HCVAb, negative human&#xD;
             immunodeficiency virus (HIV) 1/2 test within 6 weeks prior to enrollment.&#xD;
&#xD;
          -  Estimated life expectancy of more than 6 months&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  WBC ≥ 2500/µL&#xD;
&#xD;
          -  ANC ≥ 1000/µL&#xD;
&#xD;
          -  Platelets ≥ 75 x 103/µL&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  AST ≤ 3 x upper limit of normal (ULN) for patients without liver metastasis&#xD;
&#xD;
          -  AST &lt; 5 x ULN for patients with liver metastasis&#xD;
&#xD;
          -  Total Bilirubin ≤ 2 x ULN&#xD;
&#xD;
          -  patients with Gilbert's Syndrome increase of indirect bilirubin &lt; 6mg/dL&#xD;
&#xD;
          -  No childbearing potential (i.e. postmenopausal, absence of menstrual bleeding for at&#xD;
             least 1 year, hysterectomy, bilateral ovariectomy or tubal section/ligation) or&#xD;
             negative pregnancy test at screening and before chemotherapy in women with&#xD;
             childbearing potential. Sexually active female patients of childbearing potential&#xD;
             should use one of the following highly effective methods of contraception (Pearl index&#xD;
             &lt; 1%): hormonal contraceptives (oral, injected, implanted, transdermal), intrauterine&#xD;
             devices or systems (e.g. hormonal and non-hormonal IUD), or vasectomized sexual&#xD;
             partner for at least 1 month before the trial start, during the course of the trial&#xD;
             and in the 6 months following dosing. Sexual abstinence is restricted to true&#xD;
             abstinence ( in line with the preferred and usual lifestyle of the subject).&#xD;
&#xD;
          -  male patients, unless surgically sterile, must be using two acceptable methods for&#xD;
             contraception (e.g. spermicide and condom) during the trial and refrain from fathering&#xD;
             a child throughout the trial and for up to 12 months after dosing.&#xD;
&#xD;
          -  Signed and dated informed consent before conduct of any trial-specific procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any evidence of brain metastases&#xD;
&#xD;
          -  CNS (central nervous system) disorders and previous strokes, if clinically relevant&#xD;
&#xD;
          -  Patients with epilepsy&#xD;
&#xD;
          -  Clinically relevant autoimmune disorders or history of clinically relevant autoimmune&#xD;
             disorders&#xD;
&#xD;
          -  Patients with T-cell lymphoma&#xD;
&#xD;
          -  Treatment with anti-CD20 antibodies or checkpoint blockade inhibitors within 6 weeks&#xD;
             before leukapheresis&#xD;
&#xD;
          -  Chemotherapy within 6 weeks prior to leukapheresis&#xD;
&#xD;
          -  History of primary immunodeficiency&#xD;
&#xD;
          -  Creatinine clearance &lt; 50 ml/min calculated according to the modified formula of&#xD;
             Cockcroft and Gault&#xD;
&#xD;
          -  concurrent systemic radiotherapy&#xD;
&#xD;
          -  Use of systemic corticosteroids and immunosuppressive medication except prednisone ≤&#xD;
             10 mg QD or equivalent&#xD;
&#xD;
          -  Patients with severe cardiac disease (e.g. NYHA Functional Class III or IV, myocardial&#xD;
             infarction within 6 months before inclusion, ventricular tachyarrhythmia requiring&#xD;
             ongoing treatment, unstable angina pectoris)&#xD;
&#xD;
          -  Other investigational treatment within 4 weeks before MB-CART20.1 infusion&#xD;
&#xD;
          -  Hypersensitivity against any drug or its ingredients/impurities that is scheduled or&#xD;
             likely to be given during trial participation, e.g. as part of the mandatory&#xD;
             lymphodepletion protocol, pre-medication for infusion, rescue medication/salvage&#xD;
             therapies for treatment related toxicities&#xD;
&#xD;
          -  Patients in which such medication (likely to be given during trial participation) is&#xD;
             contraindicated for other reasons than hypersensitivity, e.g. live vaccines and&#xD;
             fludarabine.&#xD;
&#xD;
          -  Severe pulmonary disease (DLCO and/or FEV1 &lt; 65%, dyspnoea at rest)&#xD;
&#xD;
          -  Active systemic fungal, viral or bacterial infection&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patient's lack of accountability, inability to appreciate the nature, meaning and&#xD;
             consequence of the trial and to formulate his/her own wishes correspondingly&#xD;
&#xD;
          -  Patients who have a relationship of dependence or employer employee relationship to&#xD;
             the sponsor or the investigator&#xD;
&#xD;
          -  Committal to an institution on judicial or official order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Borchmann, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Köln</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Schubert</last_name>
    <phone>+49 2204 8306 6564</phone>
    <email>christines@miltenyibiotec.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Karitzky, Dr.</last_name>
    <phone>+49 2204 8306 6560</phone>
    <email>sandrak@miltenyibiotec.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Cologne - Clinic for Internal Medicine I</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Borchmann, Prof. Dr.</last_name>
      <phone>+49 221 478</phone>
      <phone_ext>88159</phone_ext>
      <email>peter.borchmann@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Udo Holtick, PD Dr.</last_name>
      <phone>+49 221 478 4407</phone>
      <email>udo.holtick@uk-koeln.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

